rebound in other trials, the latter result being probably linked to inappropriate immune activation.
4. The most recent tendency is to target dendritic cells with either inactivated autologous virus or virus antigenencoding RNA. Safety and ímmunogenicity of this strategy has been well established, but clinical results are equivocal as yet. In any case, this approach is amendable to further refinement, with regard to inclusion of RNA encoded patient-adapted viral sequences and co-stimulatory molecules, as well as improved targeting.
In conclusion, several HIV immunotherapy strategies are being attempted, with varying success. The basic challenge remains to find a (combined) strategy, successfully activating effective HlV-specific T cell responses, while reducing inappropriate HIV-promoting immune activation. 
